Register

Medical Oncology

Gynecologic Cancers   

Questions discussed in this category

Would development of a rectovaginal fistula mid-treatment with second line pembrolizumab/lenvatinib for endometrial cancer cause you to change regimens, eliminate lenvatinib, or continue current therapy?
The patient has a history of pelvic radiation and progressed through first line carboplatin/taxol. She has had a partial response to pembro/lenvatinib...
1 Answer available
What is your response to the question, "Is this terminal?"
How do you "have the talk" in a way that is straightforward without emotionally crushing the patient?
8 Answers available
How would you treat a recurrent endometrial cancer at the vaginal cuff that was initially FIGO 1A with no adj treatment, in a patient with actively treated scleroderma?
3 Answers available
Would you consider a PARP inhibitor in the treatment of a PARP inhibitor naïve platinum resistant recurrent ovarian cancer with LOH/HRD?
1 Answer available
In the setting of platinum resistant ovarian cancer, do you consider repeat use of bevacizumab with subsequent lines of chemotherapy following prior treatment with chemotherapy + bevacizumab with bevacizumab maintenance?
Considering the treatment of platinum resistant ovarian cancer as done in the AURELIA trial (Pujade-Lauraine et al., PMID 24637997).
1 Answer available
What is your institutional approach to a restrictive “neutropenic diet”?
3 Answers available
What are your top takeaways in Gynecologic Cancers from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...
2 Answers available
What is your preferred adjuvant chemotherapy regimen after a completely resected stage IIIB Granulosa Cell tumor of the ovary?
1 Answer available
Do you routinely check tumor genomics, including POLE status for new endometrial cancers?
How does the presence of specific mutations affect your adjuvant treatment planning or patient counseling?
1 Answer available
How does your approach to low-risk gestational trophoblastic neoplasia differ for patients whose hCG levels plateau following initial single agent systemic therapy vs those who have a good initial response and then plateau?
1 Answer available
How has the virtual aspect of tumor boards impacted their educational quality in the Covid-19 era?
1 Answer available
If a patient with HER2+ uterine serous carcinoma recurs while on maintenance trastuzumab, would you continue trastuzumab with second line chemotherapy?
Given data from metastatic breast cancer trials that show benefit with continuing trastuzumab despite progression.
2 Answers available
How do you proceed after a patient has a partial response following 6 cycles of cisplatin + paclitaxel + bevacizumab +/- pembrolizumab for metastatic SCC of the cervix?
Assuming minimal toxicities except fatigue from long, recurrent infusions.
2 Answers available
How do you manage real-time release of pathology and radiology results to oncology patients following enaction of the CURES act?
1 Answer available
How do you determine duration of anticoagulation for an ovarian vein thrombosis following a provoking event?
1 Answer available
Would you modify standard WPRT+brachy radiation for cervical SCC s/p negative nodal staging but aborted hysterectomy due to previously undetected superficial vaginal disease?
1 Answer available
How do you manage patients with chemotherapy-induced paronychia?
1 Answer available
In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy?
Do you stop therapy at 2 years or continue until progression of disease?
1 Answer available
What are your top takeaways from SGO 2022?
10 Answers available
Are there best practices or data regarding the use of open notes among oncology patients?
What is the impact among patients and providers? Has your documentation been adjusted now that patients can readily review?
2 Answers available
What is your adjuvant therapy for node positive, low grade endometrioid endometrial adenocarcinoma?
3 Answers available
How do you integrate ophthalmic exam and surveillance into routine visits for cervical cancer patients receiving tisotumab vedotin?
2 Answers available
Do you treat an endometrial cancer that is microsatellite-stable but has a high TMB after progressing on platinum-based therapy with pembrolizumab?
2 Answers available
What is your approach to first line systemic therapy in metastatic PD-L1 positive cervical cancer?
Do you include pembrolizumab with platinum-taxane + bevacizumab or reserve it as a second line option?
2 Answers available
What features help distinguish thyroid myopathy from immune checkpoint inhibitor-associated myopathy?
1 Answer available
How do you manage the wide array of emotions like anger and disappointment patients may have when they first learn of an incurable relapse of an early stage cancer?
How do you maintain a trusting relationship with your patients when this relapse occurs?
1 Answer available
What is your strategy for breakthrough chemotherapy induced N&V in patients receiving highly emetogenic chemotherapy and already received a NK-1 antagonist, 5-HT3 antagonist, dexamethasone, and olanzapine?
3 Answers available
What chemotherapy would you consider to treat platinum resistant high grade serous ovarian cancer in patients with a low grade MDS from prior platinum/PARPi?
Assuming low risk of progression to AML and eligible for low-risk chemotherapies per hematologic/oncology.
1 Answer available
Do you offer PARP inhibitor maintenance retreatment of platinum-sensitive, relapsed, high grade serous ovarian cancer in patients who had a complete response to their most recent platinum-based chemo?
Front-line PARP inhibitor maintenance therapy discontinued without progression.
5 Answers available
When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?
How do you decide if it may be safe to continue immunotherapy?
1 Answer available
How do you manage a screening pap smear result of HSIL and HPV16+ in a first trimester pregnancy?
2 Answers available
Does the presence of an ATM mutation in advanced stage ovarian cancer influence the decision to use Bev vs PARP inhibitor for maintenance?
2 Answers available
What adjuvant therapy do you recommend for early stage poorly differentiated small cell neuroendocrine carcinoma of the cervix after surgical resection?
2 Answers available
What is optimal therapy for a 5 year delayed recurrence of uterine cancer, rendered NED by solitary pulmonary metastasis resection?
And if the tumor is MSI-H, does that alter your thoughts?
3 Answers available
When do you transfuse cervical cancer patients undergoing chemoradiation?
Do you try to keep Hb> 10 or 12? Or somewhere in between? 
2 Answers available
What is your strategy to help prevent paclitaxel-related neuropathy?
Do you prophylactically start all patients on B12, B-complex, and/or omega-3? If so, what dose? What about ice mittens and booties?
3 Answers available
When, if ever, would you recommend risk reducing BSO in patients with moderate penetrance breast cancer germline mutations?
Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylacti...
2 Answers available
How do you counsel premenopausal women with BRCA1 or BRCA2 mutations on the need for bilateral oopherectomy?
2 Answers available
Would concurrent endocrine therapy and PARPi maintenance be safe and appropriate after surgical treatment/adjuvant chemotherapy for a patient with BRCA1 mutated synchronous early stage HR+ breast CA and Stage IIA Fallopian tube carcinoma?
1 Answer available
What is your approach to the management of hot flashes in a patient who wants to use herbal medicine?
Do you allow patients with breast cancer on tamoxifen to use black cohosh?
2 Answers available
Would you add a PARP inhibitor to bevacizumab maintenance for a patient with a high grade serous ovarian cancer with a germline BRCA2 variant of unknown significance and negative somatic testing?
1 Answer available
In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?
2 Answers available
In women of childbearing age with NMDA encephalitis and normal pelvic imaging, is there a role for oophorectomy for possible microteratoma?
If not, how often do you repeat pelvic imaging?
1 Answer available
Do you recommend adjuvant treatment for nodal isolated tumor cells in an otherwise low-risk endometrial cancer?
1 Answer available
How would you approach a primary small cell carcinoma of the vagina in a patient with an intact uterus and cervix?
1 Answer available
How would you proceed for a patient with metastatic gastric-type adenocarcinoma, with vaginal and inguinofemoral disease only, who experiences complete response to her vaginal tumor but residual inguinal disease?
History of CDH1 mutation and prophylactic gastrectomy in 2017 - no other primary site found beyond vagina at diagnosis. Vaginal tumor completely resp...
2 Answers available
How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?
3 Answers available
What strategies have you found to be most effective in engaging PCPs in a primary-care or shared-care model of survivorship for pediatric and AYA patients who will receive ongoing care in their communities away from their primary oncology treatment site?
In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients. 
1 Answer available
What is your approach to immunotherapy-related pancreatitis?
How do you manage the initial event, including length of steroid taper and the role of pancreatic enzyme monitoring? What is your experience of subse...
1 Answer available
In what scenario would you give consolidation chemotherapy after chemoradiation for stage 3 cervical cancer with a good response?
3 Answers available
Would you offer any adjuvant therapy for cervical cancer following total pelvic exenteration in the setting of a positive pelvic lymph node?
Previously received pelvic EBRT and intracavitary brachytherapy. IORT was administered to the node-positive side wall at the time of exenteration.
3 Answers available
How would you proceed after complete response to carboplatin/paclitaxel/bevacizumab in a patient who presented with distantly recurrent SCC of the cervix?
Initially treated with definitive chemoRT but recurred with distant mets. Completed 6 cycles carb/tax/bev with minimal toxicity. Excellent performance...
1 Answer available
What chemotherapy would you utilize for a metastatic dysgerminoma diagnosed in the second trimester of pregnancy?
1 Answer available
How would you manage a patient with history of locally advanced SCC of the cervix, treated with definitive chemoRT, found to have new lung lesions 6 months post treatment?
Lung is biopsy proven met cervix, SBRT is planned. 
2 Answers available
What would be your treatment approach for a patient with a new PET positive para-aortic node 3 months following completion of definitive chemoradiation for locally advanced cervical cancer?
Patient did not previously receive para-aortic radiation. Considering RT vs RT  + chemo vs chemo alone
1 Answer available
How do you manage cancer treatment-related cognitive change or "chemo brain?"
Are there any effective non-pharm or pharm interventions?
1 Answer available
How would you approach treatment for centrally recurrent cervical SCC with positive margins after excision that was not exenteration?
Recurrence was 2cm and PET confirmed local. Excision with positive margins. Current plan for salvage whole pelvic RT and vaginal cuff brachytherapy +/...
3 Answers available
How would you treat an advanced stage small-cell carcinoma of the ovary, hypercalcemic type? (SCCOHT)?
s/p optimal debulking. If this was an early-stage cancer would it change your adjuvant therapy recommendations?
1 Answer available
How would you adjust therapy for a patient with high risk, stage III choriocarcinoma (lung mets) in the context of renal insufficiency (Cr 3.8)?
1 Answer available
What chemotherapy regimen would you utilize for a metastatic, poorly differentiated carcinoma of the cervix with neuroendocrine features?
If confirmed neuroendocrine and PD-L1 pending, how would you treat?
3 Answers available
How would you manage a patient with history of stage IIIC HGSOC after secondary cytoreduction of isolated inguinal node recurrence 12 years after primary treatment?
Recurrence picked up incidentally on CT. No germ line mutations, somatic tumor testing of node resulted negative. PET confirmed isolated recurrence
1 Answer available
What is your strategy to prevent and treat constipation in patients initiating or receiving opioids?
What non-pharmacological interventions do you recommend? Do you routinely prescribe prophylactic laxatives to patients initiating opioids? How do you ...
3 Answers available
Would you recommend PARP inhibitor maintenance for a BRCA wild-type, HRD+ advanced ovarian cancer?
2 Answers available
How long would you continue second line maintenance PARP inhibitor in a patient with recurrent stage IV BRCA+ ovarian cancer who had CR and remains NED?
Do you extrapolate from first line maintenance studies for duration of therapy?
6 Answers available
After an optimal tertiary cytoreduction for recurrent granulosa cell tumor previously treated with BEP and hormonal therapy, would you recommend systemic chemotherapy?
Initial diagnosis was 15+ years ago
2 Answers available
Is there any role for PARPi maintenance in BRCA-/HRD- patients after response to front line chemotherapy +/- bevacizumab?
2 Answers available
What factors impact your decision to include bevacizumab with primary chemotherapy for patients with BRCA+ or HRD+ ovarian cancer?
Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses? 
4 Answers available
Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
3 Answers available
What is your current practice for obtaining mutation status for a patient with newly diagnosed ovarian cancer?
What specific platforms for determining somatic BRCA and HRD status do you use for a patient who does not carry a germline BRCA mutation?
3 Answers available
How would you treat/counsel a patient with Stage IB3 SCC of the cervix who is 18 weeks pregnant and desires to maintain pregnancy?
1 Answer available
Is there a role for reassessing somatic mutation status at relapse in patients with epithelial ovarian cancer?
If yes, what type of testing platform would you use?
2 Answers available
When would you continue bevacizumab versus using PARPi alone for maintenance therapy in BRCA+ or HRD+ ovarian cancer after response to primary platinum + bevacizumab?
Are there clinical factors which help stratify? Does your practice vary based on mutation status (BRCA+ vs HRD+?)
3 Answers available
Which PARP inhibitor do you recommend for maintenance therapy in BRCA+ ovarian cancer after primary chemotherapy and why?
How do the 5 year results of SOLO-1 at ESMO 2020 impact your recommendations?
3 Answers available
How do you logistically give sandwich chemotherapy and whole pelvis radiation treatment in advanced endometrial cancer?
How many cycles do you prefer before and after? How long do you tend to wait before starting radiation after initial chemo and after radiation to resu...
1 Answer available
How do you advise patients on duration of first line maintenance PARPi and the potential risk of MDS or AML?
Is MDS/AML risk increased with longer duration of therapy?
2 Answers available
What are the current official guidelines regarding COVID-19 vaccination for patients with cancer or for hematologic conditions?
2 Answers available
When might you recommend adjuvant chemotherapy for fully staged/resected stage IA clear cell ovarian carcinoma?
2 Answers available
How would you treat metastatic squamous cell carcinoma arising from a mature cystic ovarian teratoma?
1 Answer available
How do you counsel patients who are candidates for a clinical trial regarding their options?
Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?
2 Answers available
How do you perform geriatric assessment for cancer patients?
Do you use specific tools or take into account certain factors when considering treatment options for older adults?
1 Answer available
If a patient with recurrent endometrial cancer experiences minimal or slow disease progression on pembrolizumab or pembro/lenvatinib, would you consider continuing or would you change agents?
Patient has tolerated combination therapy well to date.
1 Answer available
How would you approach diagnosis of residual ovarian tissue in a patient with ER positive breast cancer, history of BSO, and a rising estradiol level on tamoxifen?
1 Answer available
Would you consider retrying a platinum based chemotherapy agent in a platinum resistant ovarian cancer patient?
3 Answers available
In what scenario would you prefer weekly vs every 3 week carboplatin/paclitaxel for high grade serous ovarian cancer?
3 Answers available
How are you counseling HR-proficient ovarian cancer patients about front line PARP inhibitor maintenance?
Given recent approval of niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or prima...
2 Answers available
How would you counsel a patient regarding possibility of ovarian preservation at time of surgery for malignant mesothelioma initially discovered in a myomectomy specimen and involving peritoneal surfaces?
Patient is 34yo and G0 referred from surgical oncology. Laparoscopic specimens of myoma and what appeared to be adhesions were significant for maligna...
1 Answer available
How does positive p53 staining influence your recommendation for adjuvant therapy in comprehensively staged early (stage IA or IB), grade 2, endometrioid endometrial cancers? 
If patient meets high intermediate risk criteria, would you consider chemotherapy in addition to radiation?
1 Answer available
Would the presence of multifocal LVSI change your adjuvant treatment recommendation for a surgically staged IA dedifferentiated endometrial carcinoma?
Does not technically meet high intermediate risk criteria.
2 Answers available
Do you re-test patients who test positive for COVID-19 during or prior to starting cancer treatment?
There are mixed recommendations about re-testing vs simply waiting for a quarantine period prior to resuming therapy. 
2 Answers available
Would you consider HRT after BSO in a pre-menopausal gBRCA2+ patient who has no intention of ever having prophylactic bilateral mastectomies and who declines chemoprophylaxis?
2 Answers available
How would you manage a recurrent uterine leiomyosarcoma, now status post secondary cytoreduction, with no gross residual disease?
Would you consider adjuvant chemotherapy, radiation therapy, hormone therapy, or surveillance?
1 Answer available
Do you routinely prophylactically anticoagulate patients undergoing systemic chemotherapy outside of the perioperative period?
1 Answer available
How would you manage a young woman with vulvar langerhans cell histiocytosis and positive margins after wide local excision?
1 Answer available
How do you sequence chemotherapy with radiotherapy for advanced endometrial cancer?
4 Answers available
Are you offering PARP inhibitor alone or both PARP inhibitor and bevacizumab maintenance for HRD+ ovarian cancer patients after upfront treatment?
Based on recent PAOLA-1
1 Answer available
Are there scenarios that new visits/consults with patients can be done virtually amidst the COVID-19 outbreak?
6 Answers available
Is it safe to treat checkpoint inhibitor-induced arthritis with methotrexate or biologics?
1 Answer available
What adjuvant therapy would you offer a patient with Stage II uterine serous carcinoma without lymph node sampling?
3 Answers available
How do you approach the pharmacologic management of cancer-related fatigue?
After optimizing symptoms and reversible factors, and attempting cognitive-behavioral interventions and exercise, do you recommend pharmacologic agent...
2 Answers available
How would you manage a Stage IB endometrioid endometrial cancer, status post staging surgery, with a rapid vaginal recurrence <1 month post operatively?
This case involves an impressive ‘high volume’ vaginal recurrence and patient was not originally planned for adjuvant therapy. Concerned t...
2 Answers available
Would you offer adjuvant therapy following successful resection of a solitary lung recurrence of leiomyosarcoma if no other evidence of recurrent disease on PET CT?
1 Answer available
What starting dose of lenvatinib are you ultilizing in recurrent endometrial cancer patients initiating lenvatinib/pembro?
1 Answer available
Would you recommend systemic therapy in a patient with a history of Stage III high grade serous endometrial cancer s/p resection of a solitary pulmonary metastasis after a long disease free interval?
Does residual grade 1-2 neuropathy from Taxol/ carbo 10 years ago affect your recommendation?
2 Answers available
What upfront maintenance therapy would you recommend for a BRCA negative, advanced epithelial ovarian cancer patient after completing adjuvant carboplatin, paclitaxel, bevacizumab?
1 Answer available
Do you recommend concurrent chemotherapy with XRT for inoperable patients with stage I-II high-risk endometrial carcinoma?
Ie for patients who are inoperable due to comorbidities?
2 Answers available
Would you recommend maintenance therapy with a PARP inhibitor for BRCA+ patients with advanced uterine serous cancer?
Since no data exists or is pending, and the two disease processes are similar, should we consider PARP inhibition in this setting? This is assumi...
1 Answer available
How do you approach the decision of whether and when to initiate therapy in patients who remain COVID-19 positive >2 weeks after infection but are asymptomatic from the virus?
E.g. a patient with progression of their primary cancer but still is testing COVID19+ over a month after infection?
5 Answers available
How do you talk to patients about clinical trials?
I care deeply about clinical trials but have always struggled on how to approach this topic. I would really appreciate tips from those of you who have...
5 Answers available
When will theMednet release an app for the iPhone?
2 Answers available
When, if ever, would you recommend hysterectomy after chemoradiation for patients with locally advanced cervical cancer?
This has been a common practice in the community. Is there a benefit for certain patients?
2 Answers available
How do you manage taxane acute pain syndrome (TAPS)?
Can it be prevented? How do you evaluate patients? What non-pharmacologic or pharmacologic interventions do you use for treatment?
1 Answer available
How do you decide the right time to transition to hospice?
Obviously, patient and caregiver preferences are paramount. But, what factors do you consider? Does expanded hospice (e.g., Medicare Care Choices) inf...
4 Answers available
Would you give a PARP inhibitor, and at what dose, to a patient with end-stage renal disease on hemodialysis after completion of 6 cycles of carboplatin and paclitaxel for advanced ovarian cancer?
1 Answer available
Should our selection for neoadjuvant chemotherapy in ovarian cancer patients change in light of COVID-19?
1 Answer available
Are maintenance therapies for ovarian cancer being held at your institution due to COVID-19?
2 Answers available
Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?
2 Answers available
How should you manage a COVID-19 infected/suspected patient who is receiving chemotherapy and cannot interrupt or delay their cancer treatment?
2 Answers available
How should you manage a coronavirus infected/suspected patient who is receiving radiotherapy and cannot interrupt or delay their cancer treatment?
How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...
7 Answers available
What are the current official guidelines regarding managing patients during COVID-19?
3 Answers available
Should I wear gloves during a routine physical exam on an asymptomatic patient with no risk factors for COVID-19?
1 Answer available
What measures should we take regarding routine follow-up visits for well patients in surveillance during the coronavirus pandemic?
When a physical exam is important and telehealth is not a good option, should we be proactive and reschedule or should we continue to see them as sche...
2 Answers available
In a patient metastatic recurrent endometrioid endometrial cancer who has a mixed response to carboplatin and paclitaxel, what is your next choice of therapy?
 No adjuvant treatment was given upfront
1 Answer available
Is your approach to managing immune related adverse events altered at all in light of COVID-19?
2 Answers available
What adjuvant chemotherapy is preferred in primary ovarian mucinous adenocarcinoma of intestinal type?
2 Answers available
How do you explain progression free survival to patients?
5 Answers available
Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?
1 Answer available
Do you routinely offer PARP inhibitor maintenance therapy to germline BRCA1/2+, FIGO stage II serous ovarian carcinoma patients after adjuvant chemotherapy?
SOLO1 trial studied stage 3/4 patients.
1 Answer available
How do you approach adjuvant treatment of non-uterine leiomyosarcoma?
When, if ever, do you utilize adjuvant RT or chemotherapy?
2 Answers available
What is optimal timing or sequencing of therapy for patients with synchronous locally advanced triple negative breast cancer and ovarian cancer with peritoneal carcinomatosis?
2 Answers available
How would you manage a patient with synchronous breast and ovarian cancer, s/p neoadjuvant chemotherapy and surgery for ER+/HER2- breast cancer and found to have an ER+ ovarian cancer nodal metastases at TAH/BSO?
RP node with treatment related changes and surgical specimen from TAH/BSO no other foci of malignancy found. 
1 Answer available
Do you recommend frontline bevacizumab with carbo/taxol in patients with advanced epithelial ovarian and BRCA mutation who will be receiving olaparib maintenance?
1 Answer available
In light of GOG-252, are there any situations where IP chemotherapy would be preferable following debulking of advanced epithelial ovarian cancer?
1 Answer available
When do you choose dose-dense chemotherapy v. q3 week therapy in advanced epithelial ovarian cancer?
1 Answer available
What is your preferred sequence of chemotherapy regimens after patients with metastatic endometrial cancer develop resistance to carboplatin + paclitaxel?
1 Answer available
How do you choose 1st line therapy for recurrent cervical cancer?
Would you be more or less likely to use a cisplatin-containing regimen if a patient had previously responded to chemoradiation with concurrent cisplat...
1 Answer available
How do you determine which systemic therapy to recommend in the 2nd line setting for metastatic, PD-L1 NEGATIVE cervical cancer?
1 Answer available
Would you recommend EBRT/brachythrapy for any patients with stage III- IV uterine ca in light of GOG-258 data?
https://www.nejm.org/doi/full/10.1056/NEJMoa1813181
1 Answer available
Do you consider tumor mutation burden as a possible biomarker for response to immune checkpoint therapy in the second line setting for cervical cancer?
1 Answer available
Is pembrolizumab considered standard of care in the 2nd line treatment of recurrent cervical cancer?
Does the phase II KN-158 provide sufficient evidence to change management?
1 Answer available
Would you recommend 1st line pembrolizumab for PD-L1 positive recurrent/metastatic cervical cancer patient who is not a candidate for or refuses chemotherapy?
1 Answer available
When do you recommend PD-L1 testing for patients with recurrent cervical cancer?
Should this be done at the time of recurrence or after failure of 1st line therapy for recurrence?
1 Answer available
Do you typically recommend avoiding neupogen during radiation treatments?
6 Answers available
How do you decide on adjuvant therapy in a patient with a Stage IA uterine carcinosarcoma without any myometrial invasion?
The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these option...
1 Answer available
Do you recommend stopping olaratumab in patients receiving doxorubicin/olaratumab for treatment of advanced sarcoma?
Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...
1 Answer available
For a patient with carcinosarcoma of the uterus and an allergic reaction to paclitaxel, would you have any reservations about using docetaxel instead?
1 Answer available
Now that there are three FDA-approved PARP inhibitors for use in ovarian cancer (niraparib, rucaparib, olaparib), how do you decide which one to use?
2 Answers available
Should olaparib maintenance therapy be recommended in patients with BRCA-positive, advanced ovarian cancer after first line platinum-based chemotherapy?
Should this be the new standard of care based on the results from the recently published SOLO-1 trial?
1 Answer available
When do you refer a patient with metastatic ovarian cancer for upfront debulking v. neoadjuvant chemotherapy?
1 Answer available
Should women with adequately debulked ovarian cancer receive bevacizumab with chemotherapy in the adjuvant setting?
3 Answers available
How do you determine the choice of therapy for platinum resistant ovarian cancer in healthy, good performance status patients?
Two new phase 2 studies this year with apatinib/oral etoposide (AEROC) and sorafenib/topotecan (TRIAS) were released, and NCCN also lists many single ...
3 Answers available
Do you recommend bevacizumab in platinum sensitive recurrences of epithelial ovarian cancer?
Or do you wait for platinum resistance?
1 Answer available
In patients with recurrent advanced ovarian carcinoma and a hypersensitivity reaction to platinum, do you prefer a desensitization protocol to maximize response or switching to a non-platinum regimen?
1 Answer available
Is it safe and/or necessary to combine osimertinib and carboplatin/paclixel for a patient with stage IV EGFR mutated NSCLC and advanced ovarian carcinoma?
Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...
1 Answer available
What is your approach to an optimally debulked patient with Stage Ia FIGO gr 3 serous carcinoma of the ovary?
Is it reasonable to use single agent carboplatin for elderly patients?
2 Answers available
Is further workup and management required for an incidentally found small focus of neuroendocrine tumor of the endometrium?
In a patient who underwent laparoscopy for endometriosis and was found to have a 1mm focus of neuroendocrine tumor, would you recommend further surger...
1 Answer available
What is the preferred second line agent for a woman with metastatic vulvar cancer who has progressed on carboplatin/paclitaxel?
She has metastatic disease beyond the pelvis (lungs).
2 Answers available
Given the indication for rucaparib in ovarian cancer for both germline and somatic BRCA mutations, do you re-biopsy tissue at recurrence for a new somatic BRCA mutation?
2 Answers available
For a young patient with stage 4 endometrial cancer with an excellent response to anthracyclines, would you continue to give anthracyclines beyond the standard dosage cap if cardiac function remains normal by echocardiogram?
1 Answer available
How would you manage a patient with low-volume non-invasive endometrioid carcinoma that is found in both the endometrium and ovary (pN0)?
Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)? What adjuva...
2 Answers available
Which chemotherapy regimen (if any) do you recommend for palliative concurrent chemoradiation for a symptomatic patient with metastatic cervical carcinoma and CKD stage 4 (GFR 15-29)?
1 Answer available
In what situations should chemotherapy be added to adjuvant radiation therapy in a resected vuvlar SCC?
Would you add chemotherapy if there was gross residual disease, pN+ and/or ECE?
2 Answers available
How would you treat small cell cancer of the cervix?
Can the classic indications for post-hysterectomy radiation (eg. "Sedlis" and "Peter's" criteria) be applied? Does the histology change radiation dose...
1 Answer available
Should I treat a patient who doesn't know she has cancer?
My patient’s family has asked that I don’t tell her that she has metastatic cancer because it will devastate her. I am planning on palliat...
2 Answers available


Papers discussed in this category

Gynecol Oncol, 2019 Aug 16
Advanced communication: A critical component of high quality gynecologic cancer care: A Society of Gynecologic Oncology evidence based review and guide.
JAMA,
The care of the patient.
JAMA Netw Open, 2021 Apr 01
Red Blood Cell Transfusion Practices for Patients With Cervical Cancer Undergoing Radiotherapy.
Gynecologic oncology, 2010-03
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
The New England journal of medicine, 2019-06-13
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.
Lancet Oncol., 2019 Jul 22
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Gynecol Oncol, 2019 Sep
Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Gynecologic oncology, 2004-04
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence.
American journal of obstetrics and gynecology, 2010-10
Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients.
Obstetrics and gynecology, 1988-01
Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014-11
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.
Gynecologic oncology, 2015-06
Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis.
The Lancet. Oncology, 2017-09
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Cancer, 1987-10-15
Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.
Gynecologic oncology, 2015-09
Ovarian involvement in endometrioid adenocarcinoma of uterus.
Curr Oncol Rep,
Pathology of Neuroendocrine Tumours of the Female Genital Tract.
Adv Anat Pathol,
Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
Gynecologic oncology, 2014-11
Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.
N Engl J Med, 2016 Feb 25
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-01
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
The New England journal of medicine, 2011-12-29
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med, 2011 Dec 29
A phase 3 trial of bevacizumab in ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-09-10
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-06-10
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Lancet Oncol, 2017 Jun
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Lancet (London, England), 2017-10-28
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
The New England journal of medicine, 2016-12-01
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
The New England journal of medicine, 2012-04-12
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
J. Clin. Oncol.,
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.
J Clin Oncol, 2014 May 1
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Int J Gynecol Cancer, 2018 Mar
An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer.
Br. J. Cancer,
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015-02
Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
The New England journal of medicine, 2018-12-27
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Gynecologic oncology, 2018-10
Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
International journal of radiation oncology, biology, physics, 1994-06-15
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
International journal of radiation oncology, biology, physics, 2010-12-01
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-06
Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-12-15
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.
N. Engl. J. Med., 2019 Sep 28
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med, 2019 Dec 19
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Science (New York, N.Y.), 2017-07-28
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
The New England journal of medicine, 2018-05-31
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-20
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
The New England journal of medicine, 2006-01-05
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Lancet Oncol, 2013 Sep
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
J. Clin. Oncol., 2019 Apr 19
Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Lancet Oncol., 2014-06-01
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Ann Surg Oncol, 2014 Aug
Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.
Cancer,
A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2018-05-23
Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk Extremity Soft Tissue Sarcoma.
Acta Oncol, 2017 Apr 21
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Lancet Oncol., 2017 Sep 04
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Lancet Oncol., 2012 Sep 04
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Cancer management and research, 2017
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Br. J. Cancer, 2009 Feb 17
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011-05
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
Lancet Oncol., 2020 Mar 03
Risk of COVID-19 for patients with cancer.
Lancet, 2020 Feb 07
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Lancet Oncol., 2020 Feb 14
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
Ann. Oncol., 2020 Mar 26
Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China.
Current treatment options in oncology, 2018-11-15
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Gynecol. Oncol., 2019 Oct 17
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
J Oncol Pharm Pract, 2020 Jan 06
PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
Gynecologic oncology, 2007-05
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature.
Gynecol Oncol Rep, 2016 Dec 18
An ovarian mature cystic teratoma evolving in squamous cell carcinoma: A case report and review of the literature.
Gynecol Oncol,
Squamous cell carcinoma arising in mature cystic teratoma of the ovary.
BMC Cancer, 2019 Mar 11
Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review.
Clin Cancer Res, 2017 Sep 27
The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.
Oncogene, 2020 Mar 02
XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-01
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
Lancet, 2019 Nov 29
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet Oncol., 2014 Feb 28
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Lancet,
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
Gynecologic oncology, 2009-08
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Lancet Oncol.,
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Br. J. Cancer, 2018 Oct 24
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-04-10
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.
Cancer journal (Sudbury, Mass.), 2007
The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism.
The journal of supportive oncology, 2003
Glutamine does not prevent paclitaxel-associated myalgias and arthralgias.
J Clin Oncol,
Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias.
Breast Cancer (Dove Med Press), 2017 Jan 23
Docetaxel-associated myalgia-arthralgia syndrome in patients with breast cancer.
J. Clin. Oncol., 2011 Mar 28
Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.
BMC Cancer, 2017 Apr 28
Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-02-15
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
N Engl J Med, 2019 Dec 19
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
J Clin Oncol, 2020 Apr 10
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Nature, 2013-05-02
Integrated genomic characterization of endometrial carcinoma.
Gynecologic oncology, 2019-09
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
F1000Res, 2019 Jun 12
Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.
Journal of the National Cancer Institute, 2013-08-21
Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010-02
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Lancet Oncol., 2018 Feb 12
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Ann. Rheum. Dis., 2019 Sep 20
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
Blood, 2008-05-15
Development and validation of a predictive model for chemotherapy-associated thrombosis.
The New England journal of medicine, 2019-02-21
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
J Thromb Haemost, 2019 Jul 28
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.
N Engl J Med, 2018 Dec 04
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Obstet Gynecol,
Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.
JAMA,
Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Cancer Prev Res (Phila), 2019 Aug 16
Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.
Lancet, 2010-03-06
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Lancet,
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.
Gynecol Oncol Rep, 2020 Jan 30
Dedifferentiated endometrioid adenocarcinoma of the uterus: A case series and review of literature.
World J Surg Oncol, 2017 Jan 10
Dedifferentiated endometrioid carcinoma of the uterus : report of four cases and review of literature.
The New England journal of medicine, 2018-07-12
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Breast J, 2019 Jul 04
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
Lancet Oncol, 2021 Mar 18
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol, 2015 Jun 23
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
N. Engl. J. Med.,
Improved survival with bevacizumab in advanced cervical cancer.
Lancet (London, England), 2017-10-07
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-10
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol, 2019 Nov 04
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Lancet Oncol, 2021 Apr 09
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Gynecologic oncology, 2016-01
Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
Gynecol Oncol, 2020 Jul 9
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
Gynecol Oncol, 2020 Jul 25
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.
Gynecologic oncology, 1998-08
Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma.
EMBO Mol Med, 2020 Apr 29
Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases.
J Oncol, 2020 Jun 24
Pathogenesis, Assessments, and Management of Chemotherapy-Related Cognitive Impairment (CRCI): An Updated Literature Review.
Journal for immunotherapy of cancer, 2017-11-21
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
J Immunother Cancer, 2021 Feb
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
J Natl Compr Canc Netw,
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Ann Oncol,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J Immunother Cancer,
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
J Immunother Cancer,
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.
J Clin Oncol, 2021 Dec 20
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Gynecologic oncology, 2019-06
Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.
Gynecol Oncol, 2021 Mar 05
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Ann Oncol, 2021 Mar 18
Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
The Lancet. Oncology, 2014-02
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-01
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2004
Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review.
Cochrane Database Syst Rev, 2011 Jun 15
Adjuvant progestagens for endometrial cancer.
Arch Gynecol Obstet, 2009 Mar 21
Splenic metastasis from endometrial carcinoma: report of a case and review of literature.
Strahlenther Onkol, 2011 Nov 17
Hematogenous metastases in patients with Stage I or II endometrial carcinoma.
Gynecol Oncol Res Pract, 2016 Jun 17
Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review.
Gynecologic oncology, 2011-07
Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document.
BMC Cancer, 2018 May 04
Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
Gynecol Oncol, 2017 Sep 24
Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
JAMA oncology, 2019-03-01
Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
N Engl J Med, 2021 Sep 18
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011-10
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
Journal of oncology practice, 2019-01
Putting Integrative Oncology Into Practice: Concepts and Approaches.
Support Care Cancer, 2021 Aug 16
MASCC antiemetics in advanced cancer updated guideline.
Arthritis Rheumatol, 2021 Apr 01
Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Int J Gynecol Cancer, 2020 Dec 18
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
N Engl J Med, 2022 Jan 19
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Gynecol Oncol, 2020 Nov 05
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
Cancer Cell, 2020 Oct 08
Open Notes in Oncology: Patient versus Oncology Clinician Views.
J Gen Intern Med, 2021 Feb 02
Words Matter: What Do Patients Find Judgmental or Offensive in Outpatient Notes?
JAMA Netw Open, 2020 Jun 01
Frequency and Types of Patient-Reported Errors in Electronic Health Record Ambulatory Care Notes.
Practical radiation oncology, 2019-03
Impact of Open Access to Physician Notes on Radiation Oncology Patients: Results from an Exploratory Survey.
The Lancet. Oncology, 2019-05
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Nat Commun, 2021 May 03
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Blood Adv, 2017 Jun 22
Ovarian vein thrombus: to treat or not to treat?
Cancer medicine, 2018-06
Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study.
Gynecologic oncology, 2015-03
The role of systemic chemotherapy in the management of granulosa cell tumors.
Gynecologic oncology, 1999-02
Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
Gynecol Oncol, 2017 May 19
Ovarian granulosa cell tumor: A National Cancer Database study.
N Engl J Med, 2009 Jun 10
Mutation of FOXL2 in granulosa-cell tumors of the ovary.
Cancer Res, 2020 Jul 08
Mutant FOXL2 Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.
J Clin Oncol, 2022 Jun 06
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Journal of hospital medicine, 2018-08-01
Things We Do For No Reason: Neutropenic Diet.
Gynecologic oncology, 2017-02
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Lancet Oncol, 2014 Sep 28
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Lancet Oncol, 2012 Nov 16
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Lancet Oncol,
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Arthritis care & research, 2018-10
Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer.

Related Topics in Medical Oncology

Copyright © 2025 theMednet
All Rights Reserved.